Paying users zone. Data is covered by .

  • Get to Biogen Inc. for $13.99, or

  • get to whole website for at least 3 months from $49.99.

 

$13.99

Income Statement Quarterly Data

Difficulty: Beginner

Biogen Inc., Consolidated Income Statement (quarterly data)

USD $ in thousands

 
3 months ended Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013 Sep 30, 2013 Jun 30, 2013 Mar 31, 2013
Product, net
Revenues from anti-CD20 therapeutic programs
Other
Revenues
Cost of sales, excluding amortization of acquired intangible assets
Gross profit
Research and development
Selling, general and administrative
Amortization of acquired intangible assets
Acquired in-process research and development
Collaboration (profit) loss sharing
Gain (loss) on fair value remeasurement of contingent consideration
Restructuring charges
TECFIDERA litigation settlement and license charges
Gain on sale of rights
Income from operations
Other income (expense), net
Income before income tax expense and equity in loss of investee, net of tax
Income tax expense
Equity in loss of investee, net of tax
Net income
Net (income) loss attributable to noncontrolling interests, net of tax
Net income attributable to Biogen Inc.
Source: Biogen Inc., Quarterly and Annual Reports
Item Description The company
Revenues Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains. Biogen Inc.'s revenues declined from Q2 2017 to Q3 2017 but then increased from Q3 2017 to Q4 2017 exceeding Q2 2017 level.
Income from operations The net result for the period of deducting operating expenses from operating revenues. Biogen Inc.'s income from operations increased from Q2 2017 to Q3 2017 but then slightly declined from Q3 2017 to Q4 2017.
Income before income tax expense and equity in loss of investee, net of tax Sum of operating profit and nonoperating income (expense) before income (loss) from equity method investments, income taxes, extraordinary items, cumulative effects of changes in accounting principles, and noncontrolling interest. Biogen Inc.'s income before income tax expense and equity in loss of investee, net of tax increased from Q2 2017 to Q3 2017 but then slightly declined from Q3 2017 to Q4 2017.
Net income The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Biogen Inc.'s net income increased from Q2 2017 to Q3 2017 but then declined significantly from Q3 2017 to Q4 2017.
Net income attributable to Biogen Inc. The portion of consolidated profit or loss for the period, net of income taxes, which is attributable to the parent. If the entity does not present consolidated financial statements, the amount of profit or loss for the period, net of income taxes. Biogen Inc.'s net income attributable to Biogen Inc. increased from Q2 2017 to Q3 2017 but then declined significantly from Q3 2017 to Q4 2017.

Top